CONMED Stock Forecast, Price & News

-2.58 (-1.92 %)
(As of 04/13/2021 01:11 PM ET)
Today's Range
Now: $131.85
50-Day Range
MA: $126.28
52-Week Range
Now: $131.85
Volume6,042 shs
Average Volume274,867 shs
Market Capitalization$3.82 billion
P/E RatioN/A
Dividend Yield0.60%
CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for minimally invasive procedures worldwide. It offers orthopedic surgery products, including sports medicine products comprising powered resection instruments, arthroscopes, reconstructive systems, tissue repair sets, and metal and bioabsorbable implants, as well as related disposable products and fluid management systems; powered surgical instruments for use in bone orthopedic, arthroscopic, oral/maxillofacial, podiatric, spinal, and cardiothoracic surgeries; sports biologics and tissue products; and surgical visualization products. The company markets orthopedic surgery products under the Hall, CONMED Linvatec, Concept, and Shutt brands. It also offers general surgery products, such as clinical insufflation, smoke evacuation, electrosurgical, and endomechanical products; and endoscopic technologies, including diagnostic and therapeutic products for use in gastroenterology procedures, and products for the treatment of diseases of the biliary structures, as well as cardiac monitoring products comprising ECG and EEG electrodes, and cardiac defibrillation pads. The company markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. CONMED Corporation was incorporated in 1970 and is headquartered in Largo, Florida.

Industry, Sector and Symbol

Industry Electromedical equipment
Phone315 797 8375
Year FoundedN/A



Sales & Book Value

Annual Sales$955.10 million
Cash Flow$6.55 per share
Book Value$25.03 per share


Net Income$28.62 million


Market Cap$3.82 billion
Next Earnings Date4/28/2021 (Confirmed)


ConMed Clears Key Benchmark, Hitting 80-Plus RS Rating
March 23, 2021 |  finance.yahoo.com
See More Headlines


Overall MarketRank

1.64 out of 5 stars

Medical Sector

347th out of 2,016 stocks

Electromedical Equipment Industry

7th out of 61 stocks

Analyst Opinion: 1.3Community Rank: 3.3Dividend Strength: 1.7Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -
-2.58 (-1.92 %)
(As of 04/13/2021 01:11 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CNMD News and Ratings via Email

Sign-up to receive the latest news and ratings for CNMD and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

CONMED (NYSE:CNMD) Frequently Asked Questions

Is CONMED a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for CONMED in the last twelve months. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CONMED stock.
View analyst ratings for CONMED
or view top-rated stocks.

What stocks does MarketBeat like better than CONMED?

Wall Street analysts have given CONMED a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but CONMED wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is CONMED's next earnings date?

CONMED is scheduled to release its next quarterly earnings announcement on Wednesday, April 28th 2021.
View our earnings forecast for CONMED

How can I listen to CONMED's earnings call?

CONMED will be holding an earnings conference call on Wednesday, April 28th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were CONMED's earnings last quarter?

CONMED Co. (NYSE:CNMD) issued its quarterly earnings data on Tuesday, January, 26th. The company reported $0.84 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.77 by $0.07. The company earned $252.80 million during the quarter, compared to analyst estimates of $262.94 million. CONMED had a trailing twelve-month return on equity of 9.48% and a net margin of 0.04%. The firm's revenue for the quarter was down 4.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.90 EPS.
View CONMED's earnings history

How has CONMED's stock been impacted by Coronavirus (COVID-19)?

CONMED's stock was trading at $78.77 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CNMD shares have increased by 67.4% and is now trading at $131.89.
View which stocks have been most impacted by COVID-19

How often does CONMED pay dividends? What is the dividend yield for CONMED?

CONMED declared a quarterly dividend on Tuesday, February 23rd. Shareholders of record on Monday, March 15th will be paid a dividend of $0.20 per share on Monday, April 5th. This represents a $0.80 annualized dividend and a yield of 0.61%. The ex-dividend date of this dividend is Friday, March 12th.
View CONMED's dividend history

Is CONMED a good dividend stock?

CONMED pays an annual dividend of $0.80 per share and currently has a dividend yield of 0.60%. The dividend payout ratio of CONMED is 30.30%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, CONMED will have a dividend payout ratio of 26.23% next year. This indicates that CONMED will be able to sustain or increase its dividend.
View CONMED's dividend history.

What guidance has CONMED issued on next quarter's earnings?

CONMED issued an update on its FY21 earnings guidance on Wednesday, January, 27th. The company provided earnings per share guidance of $2.85-3.05 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.02. The company issued revenue guidance of $975 million - $1.02 billion, compared to the consensus revenue estimate of $1.02 billion.

What price target have analysts set for CNMD?

6 analysts have issued 12 month target prices for CONMED's shares. Their forecasts range from $76.00 to $145.00. On average, they anticipate CONMED's stock price to reach $104.60 in the next year. This suggests that the stock has a possible downside of 20.7%.
View analysts' price targets for CONMED
or view top-rated stocks among Wall Street analysts.

Who are CONMED's key executives?

CONMED's management team includes the following people:
  • Mr. Curt R. Hartman, Chairman, CEO & Pres (Age 57, Pay $2.04M)
  • Mr. Todd W. Garner, Exec. VP & CFO (Age 52, Pay $941.04k)
  • Mr. Patrick J. Beyer, Pres of International & Global Orthopedics (Age 55, Pay $927.34k)
  • Mr. Stanley W. Peters III, VP & GM of U.S. Advanced Surgical (Age 46, Pay $858.66k)
  • Mr. Nathan Folkert, VP & GM of U.S. Orthopedics (Age 46, Pay $626.98k)
  • Mr. Daniel S. Jonas, Exec. VP of Legal Affairs, Gen. Counsel & Sec. (Age 57)
  • Mr. Peter K. Shagory, Exec. VP of Strategy & Corp. Devel. (Age 52)
  • Ms. Heather L. Cohen, Exec. VP of HR (Age 48)
  • Mr. John E. Kennedy, Group Exec. VP of Patient Care & Endoscopic Technologies (Age 63)
  • Ms. Shanna L. Cotti-Osmanski, Exec. VP of Information Technology & CIO

Who are some of CONMED's key competitors?

What is CONMED's stock symbol?

CONMED trades on the New York Stock Exchange (NYSE) under the ticker symbol "CNMD."

Who are CONMED's major shareholders?

CONMED's stock is owned by a variety of institutional and retail investors. Top institutional investors include State of Alaska Department of Revenue (0.07%) and Everence Capital Management Inc. (0.01%). Company insiders that own CONMED stock include Brian Concannon, Curt R Hartman, Daniel Jonas, Dirk Kuyper, John Jed Kennedy, John L Workman, Johonna Marie Pelletier, Mark E Tryniski, Peter K Shagory, Stanley W Peters III, Terence M Berge and Wilfredo Ruiz-Caban.
View institutional ownership trends for CONMED

Which institutional investors are selling CONMED stock?

CNMD stock was sold by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue. Company insiders that have sold CONMED company stock in the last year include Brian Concannon, Curt R Hartman, Daniel Jonas, Johonna Marie Pelletier, Mark E Tryniski, Peter K Shagory, Stanley W Peters III, Terence M Berge, and Wilfredo Ruiz-Caban.
View insider buying and selling activity for CONMED
or view top insider-selling stocks.

Which institutional investors are buying CONMED stock?

CNMD stock was bought by a variety of institutional investors in the last quarter, including Everence Capital Management Inc..
View insider buying and selling activity for CONMED
or or view top insider-buying stocks.

How do I buy shares of CONMED?

Shares of CNMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CONMED's stock price today?

One share of CNMD stock can currently be purchased for approximately $131.89.

How much money does CONMED make?

CONMED has a market capitalization of $3.82 billion and generates $955.10 million in revenue each year. The company earns $28.62 million in net income (profit) each year or $2.64 on an earnings per share basis.

How many employees does CONMED have?

CONMED employs 3,400 workers across the globe.

What is CONMED's official website?

The official website for CONMED is www.conmed.com.

Where are CONMED's headquarters?

CONMED is headquartered at 525 FRENCH ROAD, UTICA NY, 13502.

How can I contact CONMED?

CONMED's mailing address is 525 FRENCH ROAD, UTICA NY, 13502. The company can be reached via phone at 315 797 8375.

This page was last updated on 4/13/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.